Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Short Talks > Session
Short Talks - Advances in Platelet Disorders: Therapeutics, Diagnostics, and Clinical Management
Moderators
Bethany Samuelson Bannow, Karen Flint
Presentations
| 10:30 |
DISCREPANT RESULTS IN VON WILLEBRAND TESTING - AN ALGORITHMIC APPROACH TO ADDRESS HETEROPHILIC ANTIBODY INTERFERENCE IN THE INNOVANCE®VWF GPIBM ACTIVITY ASSAY(THSNA TRAVEL AWARDEE) Karen E. Flint1, Jeremy D. Williams1, Joshua L. Rhodes1, Kenneth D. Friedman2, Andrea Staum2, Sandra L. Haberichter2, Bailey Hutchison2, Andrew Podd2, Lori Luchtman-Jones1,3. 1Hemostasis and Thrombosis Lab, Hematology Division, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center (CCHMC), Cincinnati, OH, USA 2Diagnostic Laboratories, Versiti/Blood Center of Wisconsin, Milwaukee, WI, USA 3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA |
|||
| 10:42 |
UTILIZE SALINE CONTROL IN HEPARIN-INDUCED THROMBOCYTOPENIA FUNCTIONAL ASSAY TO IDENTIFY HEPARIN-INDEPENDENT ANTIBODIES (THSNA TRAVEL AWARDEE) Jing Jin1, Krinaben Patel1, Lu Yang2, James Zehnder2. 1Special Coagulation, Stanford Health Care Palo Alto, CA, USA 2Department of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA |
|||
| 10:54 |
REDUCTION IN CONCOMITANT THERAPY USE WITH RILZABRUTINIB AND SUSTAINED RESPONSE IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN THE PHASE 3 LUNA3 LONG-TERM EXTENSION (LTE) PERIOD David J. Kuter1, Lei Zhang2, Waleed Ghanima3, Yoshitaka Miyakawa4, Yu Hu5, David Gómez-Almaguer6, Matias Cordoba7, Marek Wardęcki8, Larissa Mege9, Meredith C. Foster7, Ahmed Daak7, Howard A. Liebman10, Sandhya Panch11. 1Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 2Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China 3Østfold Hospital Trust, Grålum, Norway and Institute of Clinical Medicine, University of Oslo, Oslo, Norway 4Department of Hematology, Saitama Medical University, Saitama, Japan 5Wuhan Xie'he Hospital, Wuhan, China 6Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico 7Sanofi, Cambridge, MA, USA 8Sanofi, Warsaw, Poland 9Sanofi, Lyon, France 10University of Southern California, Los Angeles, CA, USA 11Fred Hutch, Fred Hutch, USA |
|||
| 11:06 |
THROMBOCYTOPENIA IN PREGNANCY: A 5-YEAR ANALYSIS OF CHARACTERISTICS AND PRACTICES FROM A SINGLE U.S. INSTITUTION Mackenzie Lemieux1, Ming Lim2. 1Division of Internal Medicine, University of Utah, Salt Lake City, UT, USA 22. Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA |
|||
| 11:18 |
RECOMBINANT VON WILLEBRAND FACTOR PROPHYLAXIS FOR SEVERE VON WILLEBRAND DISEASE: FINAL RESULTS FOCUSING ON ADULTS RECEIVING ONCE WEEKLY PROPHYLAXIS IN A PHASE 3B CONTINUATION STUDY Sophie Susen1, Frank W G Leebeek2, Giancarlo Castaman3, Amy L Dunn4, Margarita A Timofeeva5, Caitlin Montcrieff6, Maria Waliullah7, Jingmei Zhang7. 1University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France 2Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands 3Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy 4Department of Hematology, Oncology, Bone Marrow Transplant and Apheresis, Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, USA 5Federal State Budgetary Scientific Institution, Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal Medical and Biological Agency, Kirov, Russia 6Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA 7Takeda Development Center Americas, Inc., Cambridge, MA, USA |